Bermekimab
Based on 1 Customer Validation
Bermekimab (MABp1) is a human monoclonal antibody targeting interleukin-1α(IL-1α) . Bermekimab can prevent tumor-related inflammation. Bermekimab can be used in the research of atopic dermatitis.
For research use only. We do not sell to patients.
- Purity: 97.68%
- CAS No.: 1401965-15-8
- Molecular Weight:145.5 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Human IgG1 kappa
Human
IL1A
Bermekimab and promote healthy intestinal bacteria genera Akkermansia abundance increase related[2].
Bermekimab in colorectal cancer model can significantly improve the removal of the fat weight[3]
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1.5X106 THP-1 cells treated with 50 nM phorbol-12-myristate-13-acetate (PMA, HY-18739) and 5 μg/ml lipopolysaccharide (LPS, HY-D1056) for 24 hours with Bermekimab (HY-P99246, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, Human IgG1 kappa, Isotype Control (HY-P99001, blue) was used as the isotype control ,cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1401965-15-8
-
Appearance Liquid
-
Molecular Weight 145.5 kDa
-
Color Colorless to light yellow
-
SMILES
[Bermekimab]
-
Synonyms
MABp1
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. McDonald JJ, et, al. Targeting IL-1α in cancer cachexia: a narrative review. Curr Opin Support Palliat Care. 2018 Dec;12(4):453-459. [Content Brief]
[2]. Gong J, et al. Author Correction: Phase I trial of Bermekimab with nanoliposomal irinotecan and 5‑fuorouracil/folinic acid in advanced pancreatic ductal adenocarcinoma. Sci Rep. 2022 Nov 4;12(1):18731. [Content Brief]
[3]. O'Sullivan Coyne G, et al. MABp1 for the treatment of colorectal cancer. Expert Opin Biol Ther. 2017 Sep;17(9):1155-1161. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)